Chronic Kidney Disease

Nephrology·MeSH: Renal Insufficiency, Chronic

Prevalence

15000.0 / 100K

Incidence

500.0 / 100K/yr

52 drugs in development·35 companies·37 clinical trials

Drug Pipeline by Phase

Approved(13)

Drug	Company
cinacalcet	DR REDDYS LABORATORIES LTD (RDY)
doxercalciferol	Amneal Pharmaceuticals, Inc. (AMRX)
EVRENZO (爱瑞卓®) / roxadustat	KYNTRA BIO INC. (KYNB)
inpefa	LEXICON PHARMACEUTICALS, INC. (LXRX)
Jardiance	ELI LILLY & Co (LLY)
Jardiance®	ELI LILLY & Co (LLY)
korsuva / kapruvia	Tvardi Therapeutics, Inc. (TVRD)
rayaldee	REPLIGEN CORP (RGEN)
rayaldee	OPKO HEALTH, INC. (OPK)
sevelamer carbonate	DR REDDYS LABORATORIES LTD (RDY)
sevelamer carbonate	Impax Laboratories, LLC (IPXL)
Vafseo	Akebia Therapeutics, Inc. (AKBA)
XPHOZAH	ARDELYX, INC. (ARDX)

Phase 3(14)

Drug	Company
Auryxia	Akebia Therapeutics, Inc. (AKBA)
AZD4248	ASTRAZENECA PLC (AZN)
bardoxolone	REATA PHARMACEUTICALS INC (RETA)
ctap101	OPKO HEALTH, INC. (OPK)
Empagliflozin	Valneva SE (VALN)
erythropoiesis stimulating agent	GH Research PLC (GHRS)
Erythropoiesis-Stimulating Agent	Akebia Therapeutics, Inc. (AKBA)
ferric	KERYX BIOPHARMACEUTICALS INC (KERYX)
ferric citrate	Akebia Therapeutics, Inc. (AKBA)
ferumoxytol	AMAG PHARMACEUTICALS, INC. (AMAG)
ravulizumab	Hepion Pharmaceuticals, Inc. (CTRVP)
Vadadustat	Akebia Therapeutics, Inc. (AKBA)
veverimer	Tricida, Inc. (TCDA)
ziltivekimab	Novo Nordisk A/S (NVO)

Phase 2(7)

Drug	Company
cin-107	CinCor Pharma, Inc. (CINC)
erepoxen	Xenetic Biosciences, Inc. (XBIO)
lorundrostat 25mg+sglt2i qd	Mineralys Therapeutics, Inc. (MLYS)
mze782	Maze Therapeutics, Inc. (MAZE)
renal autologous cell therapy	PROKIDNEY CORP. (PROK)
tour006	Tourmaline Bio, Inc. (TRML)
tour006 -	Tourmaline Bio, Inc. (TRML)

Phase 1(5)

Drug	Company
disc-0974	Disc Medicine, Inc. (IRON)
nnc0519-0130	Novo Nordisk A/S (NVO)
ojr520	NOVARTIS AG (NVSEF)
ojr520	Novartis AG (NVS)
vonsetamig	REGENERON PHARMACEUTICALS, INC. (REGN)

Preclinical(8)

Drug	Company
electroceuticals therapeutic devices	ENDONOVO THERAPEUTICS, INC. (ENDV)
ergod2	ENTIA BIOSCIENCES, INC. (ERGO)
matloc 1	MARIZYME, INC. (MRZM)
matloc 2	MARIZYME, INC. (MRZM)
pulsevet shock wave therapy	Zomedica Corp. (ZOMDF)
RDX020	ARDELYX, INC. (ARDX)
react/gen	PROKIDNEY CORP. (PROK)
react/universal	PROKIDNEY CORP. (PROK)

Unknown(1)

Drug	Company
noninterventional	REGENERON PHARMACEUTICALS, INC. (REGN)

Phase 4(4)

Drug	Company
Baxdrostat/dapagliflozin	ASTRAZENECA PLC (AZN)
Dapagliflozin 10mg Tab	ASTRAZENECA PLC (AZN)
empagliflozin	ENANTA PHARMACEUTICALS INC (ENTA)
Zibotentan/Dapagliflozin	ASTRAZENECA PLC (AZN)

BioSniper tracks 52 drugs in development for Chronic Kidney Disease across 35 companies.

There are 37 clinical trials targeting Chronic Kidney Disease tracked by BioSniper.

The estimated prevalence of Chronic Kidney Disease is approximately 15000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.